Floatz logo

Sorafenib

Adult Angiosarcoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

50 Active assets in the Adult Angiosarcoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 2B
Encequidar
QuantumLeap Healthcare Collaborative
Phase 2CCC
Trilaciclib
QuantumLeap Healthcare Collaborative
Phase 2CCC
Rilvegostomig
QuantumLeap Healthcare Collaborative
Phase 2CCC
Metformin
QuantumLeap Healthcare Collaborative
Phase 2CCC

View all 50 →

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
SorafenibDormant
BBB
Indicative ·
75 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →